Drug
Thymoglobulin (ATG)
Thymoglobulin (ATG) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_4
1
20%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 23 (60.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
Trials by Status
completed480%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
NCT00469014
completedphase_2
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
NCT00857389
completedphase_2
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
NCT00475020
withdrawnphase_4
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT02130817
completedphase_3
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
NCT00682292
Clinical Trials (5)
Showing 5 of 5 trials
NCT00469014Phase 2
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
NCT00857389Phase 2
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
NCT00475020Phase 2
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
NCT02130817Phase 4
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT00682292Phase 3
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5